It is made available	under a CC-BY	4.0 International license
----------------------	---------------	---------------------------

The Accuracy of the Uganda National Tuberculosis and Leprosy Program algorithm and the World

2	Health Organisation treatment decision algorithms for childhood tuberculosis: A retrospective analysis				
3	Authors: Peter J Kitonsa# <sup>1,2</sup> , Bernard Kikaire <sup>2</sup> , Peter Wambi <sup>1</sup> , Annet Nalutaaya <sup>1</sup> , Jascent Nakafeero <sup>1</sup> ,				
4	Gertrude Nanyonga <sup>1</sup> , Emma Kiconco <sup>1</sup> , Deus Atwiine <sup>1,3</sup> , Robert Castro <sup>4</sup> , Ernest A Oumo <sup>1</sup> , Hellen T Aanyu <sup>3</sup> ,				
5	Mary N Mudiope <sup>5</sup> , Ezekiel Mupere <sup>2</sup> , Moorine P Sekadde <sup>6</sup> , Swomitra Mohanty <sup>7</sup> , Adithya Cattamanchi <sup>1,4,8,9</sup> ,				
6	Eric Wobudeya <sup>**1,3</sup> , Devan Jaganath <sup>**1,9,10</sup>				
7					
8	<sup>1</sup> Uganda Tuberculosis Implementation Research Consortium (U-TIRC), Walimu, Kampala, Uganda.				
9 10	<sup>2</sup> Department of Pediatrics and Child Health, College of Health Sciences, Makerere University, Kampala, Uganda.				
11	<sup>3</sup> Department of Pediatrics and Child Health, Mulago National Referral Hospital, Kampala, Uganda.				
12 13	<sup>4</sup> Division of Pulmonary and Critical Care Medicine, University of California, San Francisco, United States America.				
14	<sup>5</sup> Infectious Diseases Institute, Kampala, Uganda				
15	<sup>6</sup> National TB and Leprosy Programme (NTLP), Ministry of Health, Kampala, Uganda				
16	<sup>7</sup> Departments of Chemical and Metallurgical Engineering, University of Utah, Salt Lake City, United States				
17	<sup>8</sup> Division of Pulmonary Diseases and Critical Care Medicine, University of California, Irvine, United States				
18 19	<sup>9</sup> Center for Tuberculosis, Institute for Global Health Sciences, University of California, San Francisco, United States America				
20	<sup>10</sup> Division of Pediatric Infectious Diseases, University of California, San Francisco, United States America				
21					
22	**Co-senior authors; # Corresponding author, <u>kitonsap@gmail.com</u>				
23					
24					
25					
26					
	Page <b>1</b> of <b>13</b>				

It is made available under a CC-BY 4.0 International license .

#### 27 ABSTRACT

Diagnosing childhood pulmonary tuberculosis (TB) is a challenge, and this led the Uganda National Tuberculosis and Leprosy Program (NTLP) to develop a clinical treatment decision algorithm (TDA) for children. However, there is limited data on its accuracy and how it compares to new World Health Organization (WHO) TB TDAs for children. This study aimed to evaluate and compare the accuracy of the 2017 Uganda NTLP algorithm with the 2022 WHO TDAs for TB among children in Kampala, Uganda.

33

We retrospectively assessed children <15 years old who underwent an evaluation for TB between November 2018 and November 2022. Children were classified as per National Institutes of Health (NIH) consensus definitions. We applied the 2017 Uganda NTLP and 2022 WHO algorithms (A with chest x-ray [CXR], B without CXR) to make a decision to treat for TB or not, and calculated accuracy in reference to Confirmed vs. Unlikely TB, as well as a microbiological and composite reference standard. We compared accuracy of the Uganda NTLP algorithm to the WHO TDAs among children <10 years old.

40

A total of 699 children were included in this analysis with 64% (451/699) under 5 years, 53% (373/669)
were male, 12% (85/699) were Xpert Ultra positive, 11% (74/669) were HIV positive and 6% had severe
acute malnutrition (SAM). The Uganda NTLP algorithm had a sensitivity of 97.9% (95% CI: 96.4-99.4) and
specificity of 25.9% (95% CI: 21.2-30.7). If CXR was considered unavailable, sensitivity was 97.9% (95% CI:
96.4-99.4) and specificity 28.1% (95% CI: 23.2-33.0). Accuracy remained similar among high-risk children.
In comparison, WHO TDAs had similar sensitivity to the Uganda NTLP, but algorithm A was more specific
(32.2%, 95% CI: 26.9-37.5) and algorithm B was less specific (15.4%, 95% CI: 11.3-19.5).

48

It is made available under a CC-BY 4.0 International license .

49 Both the Uganda NTLP and WHO TDAs had high sensitivity but low specificity. The WHO TDAs had better

50 specificity than the NTLP algorithm with CXR, and worse specificity without CXR. Further optimization of

- 51 the algorithms is needed to improve specificity and reduce over-treatment of TB in children.
- 52

## 53 INTRODUCTION

54 Childhood pulmonary tuberculosis (TB) presents a diagnostic challenge due to its non-specific 55 presentation and difficulties in obtaining respiratory specimens because young children (who are most 56 vulnerable) cannot expectorate. Additionally, sputum evaluation by smear and molecular testing is often 57 negative due to the paucibacillary nature of childhood TB.<sup>[1, 2]</sup> Moreover, children often present at primary 58 care facilities, which may lack the infrastructure for molecular testing or chest X-ray (CXR) to support TB 59 evaluation and timely diagnosis. Consequently, there are large delays in TB treatment, which may explain 60 why globally only 41% of the United Nations (UN) high-level meeting target of 3.5 million children on TB treatment was achieved.<sup>[1]</sup> 61

62 To reduce the delays in TB treatment initiation for children, treatment decision algorithms (TDAs) have 63 been developed to guide providers on empiric treatment based on signs and symptoms. In Uganda, the 64 National TB and Leprosy Program (NTLP) developed an algorithm that has been implemented since 65 2017.<sup>[3]</sup> In 2022, the World Health Organization (WHO) conditionally recommended the use of TDAs for childhood TB, and presented an algorithm based on signs and symptoms as well as scores with CXR 66 (Algorithm A) or without CXR (Algorithm B).<sup>[4]</sup> However, there are limited data on the accuracy of these 67 68 algorithms, and their use may result in over- or under-diagnosis of TB among children. Moreover, it is 69 unclear if the new WHO algorithms should be utilized in Uganda or the current Uganda NTLP algorithm 70 continued or updated.

It is made available under a CC-BY 4.0 International license .

To better define the role of these algorithms, we retrospectively analyzed four years of clinical data from children in Kampala, Uganda who underwent a standard TB evaluation and were classified according to National Institutes of Health (NIH) consensus definitions for childhood TB. We utilized this data to determine the accuracy of the Uganda NTLP algorithm, and also to compare its accuracy it to the WHO TDAs in same age group, and how accuracy varied based on access to Xpert and/or CXR.

76

#### 77 MATERIALS AND METHODS

## 78 <u>Study Population</u>

De-identified data (accessed, 6<sup>th</sup> December 2022) from children aged 0 - 14 years who underwent an 79 80 evaluation for possible pulmonary TB between 28<sup>th</sup> November 2018 and 30<sup>th</sup> November 2022 was included for this analysis. The parent study recruited children from 28th November 2018 to 19th September 81 82 2024, situated at the Mulago National Referral Hospital Pediatric TB clinic within the Mulago National 83 Referral Hospital (MNRH).<sup>[5]</sup> The TB clinic recruited children from the MNRH pediatric wards, Mulago assessment center, other clinics and hospitals in and around Kampala (including Kampala Capital City 84 85 Council (KCCA) clinics/health facilities and Infectious Diseases Institute (IDI) clinics), and referrals from upcountry health facilities. After evaluation, children returned to their referring facilities for further care. 86 87 MNRH provides approximately 500,000 outpatient visits per year including from specialized clinics.<sup>[5]</sup> The 88 hospital's immediate catchment area includes Kampala, Mukono and Wakiso districts with a population 89 of approximately 1.8, 0.9 million and 3.4 million respectively<sup>[6]</sup> with the main languages spoken being 90 Luganda and English. The hospital is also a national center of excellence that attends to patients from the 91 entire country.

92 Children were consecutively enrolled and included if they had cough at least 1 week and at least two of
93 the following: unexplained fever >1 week, weight loss (>5% reduction compared to highest recorded

It is made available under a CC-BY 4.0 International license .

weight in prior 3 months), poor appetite, poor weight gain/failure to thrive (weight-for-age or weight-forheight/length z-scores ≤-3), unexplained lethargy or reduced playfulness >1week, abnormal chest x-ray or
history of TB contact. Children who were already on TB treatment, or history of TB disease in the last year,
were excluded. Our analysis was restricted to children who met the Uganda intensified TB case finding
(ICF) guide<sup>[3]</sup> definition of presumptive TB applied at all entry points: any one of persistent cough ≥2 weeks
or any duration if HIV positive: persistent fevers ≥2 weeks: poor weight gain in the last ≥1 month; TB
contact, or swellings in the neck, armpit or groin.

#### 101 <u>TB evaluation procedures</u>

Participants completed an interview, which included a standardized questionnaire about TB symptoms and signs and the duration of each, along with questions about their sociodemographic information and potential TB risk factors. The clinical evaluation included physical examination, CXR, Tuberculin skin testing (TST), and HIV testing. Respiratory specimen collection included expectorated or induced sputum, gastric aspiration, or nasopharyngeal aspiration, and was sent for Gene Xpert MTB/RIF Ultra testing (Cepheid, Sunnyvale, USA) and solid or liquid mycobacterial culture. Xpert Ultra trace semi-quantitative results were considered positive. Additional details have been previously published.<sup>[7]</sup>

All individuals had their weight (in kg) and height/length (in meters) taken using a weighing scale and SECA-216 stadiometer (Seca Industries, Hamburg), respectively. All children had a follow up visit regardless of TB diagnosis at 2 months to assess ongoing or resolved signs and symptoms and any response to anti-TB treatment.

## 113 <u>Classification of TB status by Treatment Decision Algorithms</u>

According to the NTLP algorithm<sup>[3]</sup>, if a child < 15 years old meets ICF criteria for presumptive TB, it is recommended to obtain a respiratory specimen for molecular testing with Xpert MTB/RIF Ultra. If MTB detected, they are treated for TB. If MTB is not detected, decision to treat was based on whether they

It is made available under a CC-BY 4.0 International license .

117 met  $\geq 2$  of the following criteria if HIV negative OR  $\geq 1$  criteria if HIV positive; 1. 2 or more TB symptoms 118 (persistent fever $\geq 2$  weeks, persistent cough $\geq 2$  weeks, poor weight gain  $\geq 1$  month), 2. positive history of 119 TB contact (bacteriologically confirmed), 3. CXR suggestive of TB, and 4. any physical signs suggestive of 120 TB. Physical signs suggestive of TB included: severe malnutrition, cervical, axilla or groin 121 lymphadenopathy, features of pneumonia not responding to broad spectrum antibiotics.

The 2022 WHO TB treatment decision algorithms (TDAs) A and B were developed for children <10 years old, and so analysis was limited to this age group.<sup>[8]</sup> The algorithms both recommend molecular testing for children with presumptive pulmonary TB. If negative or unavailable, a TB score is calculated that assigns points to TB signs and symptoms, with TB treatment decision when the total score  $\geq$ 10. The algorithms differ in whether CXR is available (A) or is not (B), with corresponding different scores assigned to the TB features.

We analyzed TB treatment decisions for four scenarios: (1) when Xpert and CXR is available; (2) when only CXR is available; (3) when only Xpert is available; and (4) when neither Xpert nor CXR is available. The Uganda NTLP algorithm was also evaluated for all the four scenarios, and WHO algorithm A for (1) and (2), and algorithm B for (3) and (4).

#### 132 Reference Standard

133 Children were classified as Confirmed TB (positive Xpert or culture), Unconfirmed TB (negative 134 microbiological testing but consideration of other signs and symptoms of TB and response to TB 135 treatment) or Unlikely TB (not meeting other criteria) using the NIH consensus definitions.<sup>[9]</sup> They were 136 unclassifiable if there was insufficient data to determine TB status. Two pediatric TB experts classified 137 each participant independently and blinded to the TDA calculation, with a third reviewer as a tiebreaker 138 if needed. We used the following reference standards:

- 139
- 1. **Confirmed TB versus Unlikely TB**. This excludes children with Unconfirmed TB.

It is made available under a CC-BY 4.0 International license .

- Composite reference standard (CRS). Confirmed or Unconfirmed are defined as TB, and Unlikely
   as not having TB.
- 142 3. Microbiologic reference standard (MRS). Confirmed TB was defined as TB, and Unconfirmed or
- 143 Unlikely TB as not having TB.
- 144 <u>Statistical methods</u>

Descriptive statistics were computed to describe relevant characteristics, and categorical variables were summarized using frequencies and proportions and all continuous variables were summarized using medians and interquartile range (IQR). Our primary objective was to determine the accuracy of the algorithms. Utilizing each reference standard above, we calculated the sensitivity and specificity of the Uganda NTLP algorithm (children <15years) and the WHO TDAs (children <10 years) for the overall and for key subgroups of children <5 years old, with SAM, or living with HIV.

- 151 We further compared the accuracy of the Uganda NTLP algorithm with that of the WHO TDAs, among
- 152 children <10 years. We compared the sensitivity and specificity of each algorithm using McNemar's test,
- 153 with significance defined as p-value < 0.05.
- 154 Stata version 13.0 (Statacorp, College Station, USA) was used for this analysis.<sup>[10]</sup>

# 155 <u>Ethical Considerations</u>

- 156 The study was approved by the Ethics Review Committee of the Makerere University School of Medicine
- 157 Research and Ethics Committee as well as the Mulago Hospital Research and Ethics Committee,
- 158 Kampala, Uganda (IRB number 12884), and the institutional review board at the University of California,
- 159 San Francisco (UCSF), United States. All children 8 to <15 years provided informed written assent and
- 160 parental/guardian written consent where as children <8 years, only parental/guardian informed written
- 161 consent was obtained for all study activities.

It is made available under a CC-BY 4.0 International license .

#### 162 RESULTS

#### 163 Participant characteristics and TB.

164 Between November 2018 to November 2022, there was a total of 875 children with TB symptoms of whom

- 165 867 met the intensified TB case finding (ICF) criteria, and of whom 842 were enrolled into the study (Figure
- 166 1). TB status was unclassifiable for 143 participants and 25 did not consent; and were excluded. We thus
- analyzed data from a total of 699 children, of whom 98 (14.1%) had Confirmed TB, 361 (51.6%) had
- 168 Unconfirmed TB, and 240 (34.3%) had Unlikely TB.
- 169 The participants' median age was 3 years (Interquartile Range, IQR: 1-6), 53% (373/699) were male, 64%
- 170 (451/699) were aged <5 years, 92% (642/699) were aged <10 years, 57% (399/699) had history of TB
- 171 contact, and 6% (42/699) had severe acute malnutrition (SAM). There were 74 (11%) children with HIV
- 172 (CHIV), and 12% (85/699) of children had a positive Xpert result (Table 1).
- 173 Diagnostic accuracy of the Uganda NTLP Algorithm
- 174 When CXR was available, the overall sensitivity was 97.9% (95% CI: 96.4-99.4) among Confirmed vs.
- 175 Unlikely TB, 90.7% (95% CI: 88.5-92.9) with the CRS, and 97.9% (95% CI: 96.4-99.4) with MRS. Specificity
- was 25.9% (95% CI: 21.2-30.7) in reference to Confirmed vs. Unlikely TB and the CRS, and 17.1% (95% CI:
- 177 14.3-20.0) with the MRS. (Table 2)
- When CXR was unavailable, the sensitivity remained the same in reference to Confirmed vs. Unlikely TB and the MRS, and reduced modestly with the CRS from 90.7% to 88.4%. In contrast, there were small increases in specificity and ranged from 19.7% to 28.1%. (Table 2)
- 181
- 182 Accuracy of the Uganda NTLP algorithm by risk group
- 183 We evaluated the accuracy of the NTLP algorithm among children less than 5 years, CHIV, and those with
- 184 SAM (Table 3). For each reference standard, the sensitivity and specificity remained similar to the overall

It is made available under a CC-BY 4.0 International license .

estimate with overlapping confidence intervals. Similar to the overall estimate, the specificity slightlyincreased without CXR.

187

## 188 Accuracy of the WHO algorithms A and B

189 The accuracy of the WHO TDAs (children <10 years) is shown in Table 2. Similar to the NTLP, sensitivity

190 was high but specificity was low across reference standards. However, in contrast, specificity varied

depending on availability of CXR, with higher specificity when CXR was available for WHO algorithm A.

192

193 *Comparison of the diagnostic accuracy of the 2017 Uganda NTLP algorithm and the 2022 WHO childhood* 

- 194 <u>TB diagnosis algorithms</u>
- 195 Among children <10 years, the accuracy of the Uganda NTLP algorithm and the WHO TDAs varied
- depending on the availability of Xpert and/or CXR (Table 4). We found that across the scenarios, the
- 197 sensitivity between the Uganda NTLP and WHO TDAs remained similar, except WHO TDA-B had higher
- sensitivity compared to Uganda NTLP algorithm when CXR was not available against the CRS only (94.2%

199 vs. 87.5% without CXR or Xpert, difference of -7.0, [95% CI: -10.7, -3.2], p <0.01). Specificity depended

200 on the availability of CXR; if CXR was available, WHO TDA-A was more specific than the Uganda NTLP

- 201 algorithm regardless of Xpert access. However, if CXR was unavailable, specificity was lower in WHO
- 202 TDA-B compared to Uganda NTLP algorithm, across reference standards.
- 203

# 204 DISCUSSION

In this study, we sought to determine the accuracy of the Uganda NTLP algorithm and also compare its accuracy to the WHO TDAs. We found that the Uganda NTLP algorithm had a high sensitivity but low specificity, under both microbiologic and composite reference standards, and the accuracy remained

It is made available under a CC-BY 4.0 International license .

similar (high sensitivity and low specificity) in key risk groups (children < 5 years, CHIV, or SAM). Both the</li>
 WHO TDA and the Uganda NTLP algorithms had similarly high sensitivity, but specificity was higher for the
 WHO TDA-A in settings with CXR available, while the Uganda NTLP algorithm had higher specificity in
 settings without molecular testing and/or CXR. Our findings point to the need for tools to augment the
 specificity of these algorithms, especially if molecular testing or CXR is not available.

213

214 The high sensitivity of the Uganda NTLP algorithm supports the goal of reducing missed TB cases, and 215 previous work has shown that this algorithm increased TB notification among children (<15 years of age) in two Ugandan districts by 41% over an 18-month period.<sup>[11]</sup> However, our study raises concern that a 216 217 large proportion of children are overtreated for TB. As children in the general population are already 218 screened first for symptoms or risk factors prior to utilizing the Uganda NTLP algorithm, greater specificity 219 is needed. For the CRS, we found a small reduction in sensitivity when children with Unconfirmed TB were 220 included, as expected given this is a heterogenous group and may include children without true TB 221 disease. Our results were in contrast to an individual participant data (IPD) meta-analysis that showed the 222 Uganda NTLP algorithm to have a lower sensitivity of 67% and higher specificity of 39%,<sup>[12]</sup> though there 223 was wide heterogeneity across studies, with a range of 33-97% sensitivity and 15-85% specificity. 224 However, across reference standards, the sensitivity remained high and specificity was low, with 225 implications for overtreatment of children. This was also true in subgroup analysis looking at CHIV, SAM, 226 or below 5 years old. It may be appropriate to over-treat these higher risk groups, but further work is 227 needed to understand the potential harms including side effects or missed alternative diagnoses.

228

The accuracy of the WHO TDAs was consistent with the IPD meta-analysis that found the pooled sensitivity and specificity at 80% and 30% respectively.<sup>[12]</sup> Our higher sensitivity may be explained by the

It is made available under a CC-BY 4.0 International license .

231 fact that children in our study were first screened using a more sensitive ICF, as similarly seen among 232 adults in Kampala where there was a 6% increase in TB case notifications as a result of ICF 233 implementation.<sup>[13]</sup> Comparing the Uganda NTLP algorithm and WHO TDAs, the sensitivity remained high 234 regardless of Xpert, reflecting that these have been developed in particular for empiric treatment when 235 microbiological testing is not available or frequently negative, given paucibacillary disease in children. The 236 Uganda NTLP algorithm's accuracy remained stable with or without CXR, unlike the WHO TDA's specificity 237 that dropped in scenarios where CXR was unavailable. A possible reason for this is how each algorithm is 238 scored. For the Uganda NTLP algorithm, the presence or absence of specific signs or symptoms are equally 239 weighted, and so more children may be diagnosed with TB for example regardless of CXR findings. In 240 contrast, the WHO TDAs assign points that differentially weight signs and symptoms, including specific 241 CXR findings. Moreover, the assigned points are different whether CXR is present or not, and the internal validation data showed that the model with CXR had greater specificity.<sup>[12]</sup> From an implementation 242 243 perspective, the WHO TDAs and algorithms with a similar approach may be most valuable in settings with 244 both Xpert and CXR available, but those are facilities where providers may have more experience with 245 diagnosing TB. Although the Uganda NTLP algorithm had lower specificity, this was higher than WHO algorithm B and it remained stable with or without CXR; it therefore may be preferable in lower-level 246 247 health facilities which may not have molecular or radiological testing facilities. Policy makers will need to 248 balance the benefits of detecting more cases with the costs of over-treatment and expanding access to 249 molecular testing with CXR to improve specificity.

250

Our study adds much needed data on the accuracy of the Uganda NTLP algorithm and its comparison to the WHO TDAs. We further present the accuracy results based on availability of CXR and Xpert to guide how these algorithms may perform in different types of settings. However, our study had limitations. The CRS is challenging because Unconfirmed TB can be greatly influenced by provider treatment initiation,

It is made available under a CC-BY 4.0 International license .

which in turn may have been informed by the NTLP algorithm given it is implemented at the facility. Therefore, we will have high incorporation bias as the CRS includes both Xpert, CXR and clinical decision to treat. Another limitation is that we looked at urban children with presumptive TB and therefore our results may not generalize to rural or migratory populations. Additionally, the assessment was done by study staff focused on the evaluation of TB and all children provided respiratory samples, which could reduce generalizability. Also, our analysis was restricted to only children who fulfilled the ICF criteria; however, only eight children were excluded as a result of this requirement.

In summary, our study shows that if implemented in its current form, the Uganda NTLP algorithm and WHO TDAs have high sensitivity to capture most cases of childhood TB, but may result in overdiagnosis and overtreatment of children without TB. Our study further highlights a potential limitation of implementing the WHO TDAs over the Uganda NTLP algorithm in primary care clinics without access to CXR or molecular testing. As new TB diagnostics emerge, it will be important to integrate them into TDAs to assess incremental changes in accuracy.

268

### 269 ACKNOWLEDGMENT

We thank the patients, families, and staff at Mulago National Referral Hospital, Kampala Capital City
Authority Clinics, and Infectious Diseases Institute (IDI) clinics. The study was supported by the National
Institutes of Health (R01HL139717 and U01AI152087 to AC, and R01HL169449 and K23HL153581 to DJ).
The content is solely the responsibility of the authors and does not necessarily represent the official views
of the National Institutes of Health.

## 275 REFERENCES

276	1.	Organisation, W.H., <i>Global tuberculosis report 2021</i> , WHO, Editor. 2021: Geneva.
277	2.	Wobudeya, E., et al., Trend and outcome of notified children with tuberculosis during 2011-2015
278		<i>in Kampala, Uganda</i> . BMC Public Health, 2017. <b>17</b> (1): p. 963.
279	3.	Ministry Of Health, U., Manual for control and Management of Tuberculosis and Leprosy, MOH,
280		Editor. 2017.
281	4.	Organisation, W.H., WHO consolidated guidelines on tuberculosis Module 5: Management of
282		tuberculosis in children and adolescents.
283		https://www.who.int/publications/i/item/9789240046764, ed. W. Team. March, 2022.
284	5.	Ministry of Health, U. Mulago National Referral Hospital. Available from:
285		https://www.health.go.ug/sermon/mulago-national-referral-hospital/.
286	6.	Review, W.P., Uganda Demographics. 2021,
287		https://worldpopulationreview.com/countries/uganda-population.
288	7.	Jaganath, D., et al., A Prospective Evaluation of Xpert MTB/RIF Ultra for Childhood Pulmonary
289		Tuberculosis in Uganda. J Pediatric Infect Dis Soc, 2021. 10(5): p. 586-592.
290	8.	Organization, W.H., WHO operational handbook on tuberculosis Module 5: Management of
291		tuberculosis in children and adolescents.
292		https://www.who.int/publications/i/item/9789240046832, ed. P. 73-74. 2021: World Health
293		Organization.
294	9.	Graham, S.M., et al., Clinical Case Definitions for Classification of Intrathoracic Tuberculosis in
295		Children: An Update. Clin Infect Dis, 2015. 61Suppl 3(Suppl 3): p. S179-87.
296	10.	StataCorp, StataCorp. 2013. Stata Statistical Software: Release 13. College Station, TX: StataCorp
297		LP. 2013.
298	11.	Zawedde-Muyanja, S., et al., Decentralisation of child tuberculosis services increases case finding
299		and uptake of preventive therapy in Uganda. Int J Tuberc Lung Dis, 2018. 22(11): p. 1314-1321.
300	12.	Gunasekera, K.S., et al., Development of treatment-decision algorithms for children evaluated for
301		pulmonary tuberculosis: an individual participant data meta-analysis. Lancet Child Adolesc
302		Health, 2023. <b>7</b> (5): p. 336-346.
303	13.	Hermans, S.M., et al., Integration of HIV and TB Services Results in Improved TB Treatment
304		Outcomes and Earlier Prioritized ART Initiation in a Large Urban HIV Clinic in Uganda. JAIDS
305		Journal of Acquired Immune Deficiency Syndromes, 2012. 60(2): p. e29-e35.

306

# Figure 1: Study cohort flowchart



Table 1: Characteristics of enrolled children with presumptive pulmonary tuberculosis in Kamp	ala,
Uganda (n=699)	

Characteristic	n (%)		
Age Category			
< 1 year	80 (11.4%)		
1 - < 5 years	371 (53.1%)		
5 - < 10 years	191 (27.3%)		
10 - < 15 years	57 (8.2%)		
Male sex	373 (53.4%)		
Has fever <sup>1</sup>	560 (80.5%)		
Has lymphadenopathy <sup>1</sup>	332 (47.6%)		
medRxiv preprint doi: https://doi.org/10.1101/2024.11.20.24317633; this version posted November 21, 2024. The copyright holder for this preprint (which was not verticed by peep view) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.	271 (38.8%)		
Failed to gain <sup>t</sup> is made in the second seco	584 (84.0%)		
Has TB contact	399 (57.1%)		
HIV Positive <sup>1</sup>	74 (11.1%)		
Severe acute malnutrition	42 (6.0%)		
Chest X-ray interpretation <sup>1</sup>			
Normal	387 (61.5%)		
Abnormal - Equivocal	129 (20.5%)		
Abnormal - Likely TB	113 (18.0%)		
Xpert MTB/RIF Ultra Positive	85 (12.2%)		

 3 missing fever, 1 missing lymphadenopathy, 4 missing Failure to gain weight, 30 missing HIV status, and 70 missing chest-xray.

**Table 2:** Diagnostic accuracy of the 2017 Uganda national childhood TB diagnosis algorithm (NTLP) and the 2022 WHO TB diagnosis algorithms A & B under three reference standards with or without chest x-ray (CXR). Xpert results were incorporated into the TDA classification

	Confirmed TB versus Unlikely TB						
	Algorithm <sup>1,2</sup>	Sensitivity (95% CI)	Specificity (95% CI)				
	With CXR						
	Uganda NTLP	97.9 (96.4, 99.4)	25.9 (21.2, 30.7)				
	WHO Algorithm A	96.3 (94.2 <i>,</i> 98.5)	32.2 (26.9, 37.5)				
	Without CXR						
	Uganda NTLP	97.9 (96.4, 99.4)	28.1 (23.2, 33.0)				
	WHO Algorithm B	97.5 (95.8, 99.3)	15.4 (11.3, 19.5)				
medRxiv prep preprint (which	print doi: https://doi.org/10.1101/2024.11.20.24317633; this version posted November 21, 2024. The copyright hoble for this or and (CRS)						
	Algorithm It is made avail	lable under a CC-Bensitiwity (95% CI)	Specificity (95% CI)				
	With CXR						
	Uganda NTLP	90.7 (88.5, 92.9)	25.9 (22.6, 29.2)				
	WHO Algorithm A	89.3 (86.8, 91.7)	32.2 (28.5, 35.9)				
	Without CXR						
	Uganda NTLP	88.4 (86.0, 90.9)	28.1 (24.7, 31.5)				
	WHO Algorithm B	94.2 (92.4, 96.1)	15.4 (12.5, 18.2)				
	Microbiologic Reference Standard (MRS)						
	Algorithm	Sensitivity (95% CI)	Specificity (95% CI)				
	With CXR						
	Uganda NTLP	97.9 (96.8, 99.0)	17.1 (14.3, 20.0)				
	WHO Algorithm A	96.3 (94.9, 97.8)	20.4 (17.3, 23.5)				
	Without CXR						
	Uganda NTLP	97.9 (96.8, 99.0)	19.7 (16.7, 22.8)				
	WHO Algorithm B	97.5 (96.3, 98.8)	10.1 (7.7, 12.4)				

CXR- chest x-ray

WHO Algorithm A-settings with chest X-ray.

WHO Algorithm B-settings without chest X-ray

1. Algorithms were applied to the age group they were indicated for: the NTLP for children <15 years, and <10 years for the WHO TDAs

2. Xpert Ultra results included in the algorithms

**Table 3:** Accuracy of the 2017 Uganda national childhood TB diagnosis algorithm (NTLP) by risk group (Age < 5 years, SAM, and HIV) under three reference standards with or without chest x-ray (CXR) for children <15 years old.

		Confirmed TB	versus Unlikely TB			
	Group	Sensitivity (95% CI)	Specificity (95% CI)			
	Age < 5 year	S				
	With CXR	98.3 (96.5, 100.1)	29.4 (23.0, 35.7)			
	Without CXR	98.3 (96.5, 100.1)	32.3 (25.8, 38.8)			
	SAM					
	With CXR	97.6 (95.9 <i>,</i> 99.3)	25.7 (20.7, 30.7)			
	Without CXR	97.6 (95.9, 99.3)	28.1 (22.9, 33.2)			
medRxiv pre preprint (which	eptintlooi: https://doi.org/1 h was not certified by pe	0.1101/2024.11.20.24317633; this version posted November 21, 2024. The c er review) is the author/funder, who has granted medRxiv a license to display	opyright holder for this / the preprint in perpetuity.			
	With CXR	It is made available under a CC-BY 4.0 Integrational (Sec. 99.3)	25.7 (20.6, 30.7)			
	Without CXR	97.5 (95.7, 99.3)	28.1 (22.9, 33.2)			
		Composite Ref	erence Standard (CRS)			
	Group	Sensitivity (95% CI)	Specificity (95% CI)			
	Age < 5 year	S				
	With CXR	89.9 (87.0, 92.7)	29.4 (25.1, 33.7)			
	Without CXR	88.2 (85.1, 91.2)	32.3 (27.9, 36.7)			
	SAM					
	With CXR	90.6 (88.3, 92.9)	25.7 (22.2, 29.1)			
	Without CXR	88.9 (86.5, 91.4)	28.1 (24.5, 31.6)			
	HIV					
	With CXR	90.5 (88.2, 92.8)	25.7 (22.2, 29.1)			
	Without CXR	88.8 (86.3, 91.3)	28.1 (24.5, 31.6)			
	Microbiologic Reference Standard (MRS)					
	Group	Sensitivity (95% CI)	Specificity (95% CI)			
	Age < 5 year	S				
	With CXR	98.3 (97.1, 99.5)	18.5 (14.8, 22.2)			
	Without CXR	98.3 (97.1, 99.5)	20.9 (17.1, 24.8)			
	SAM					
	With CXR	97.9 (96.8, 99.0)	19.7 (16.7, 22.8)			
	Without CXR	97.6 (96.4, 98.8)	19.1 (16.0, 22.2)			
	HIV					
	With CXR	97.5 (96.2, 98.7)	16.8 (13.9, 19.8)			



97.5 (96.2, 98.7)

19.1 (16.0, 22.2)

**Table 4:** Comparison of 2017 Uganda national childhood TB diagnosis algorithm (NTLP) against 2022 WHO childhood TB treatment decision algorithms among children <10 years old with and without Xpert testing or Chest X-ray imaging

	N	ГLР	WHO Algo	rithm A/B <sup>1</sup>		
Scenario	Sensitivity %, (95%Cl)	Specificity %, (95%CI)	Sensitivity %, (95%Cl)	Specificity %, (95%Cl)	Difference in Sensitivity (NTLP vs. WHO) % (95% Cl), p-value	Difference in Specificity (NTLP vs. WHO) % (95% Cl), p-value
Confirmed TB	Vs. Unlikely TB					
Xpert + CXR	97.6 (95.9, 99.3)	25.7(20.7, 30.7)	96.3 (94.2, 98.5)	32.2 (26.9, 37.5)	1.3 (-2.3, 4.5), 1.00	-6.8 (-11.9, -1.7), 0.01
Xpert	97.6 (95.9, 99.3)	28.1 (22.9, 33.2)	97.5 (95.8, 99.3)	15.4 (11.3, 19.5)	0 (-1.2, 1.2), 1.00	12.1 (5.3, 19.0), <0.01
CXR	93.7 (90.9, 96.5)	25.7 (20.6, 30.7)	96.3 (94.2, 98.5)	32.2 (26.9, 37.5)	-2.5 (-3.7, 8.8), 0.62	-6.8 (-11.9, -1.7), <0.01
None	91.2 (88.0, 94.5)	28.1 (22.9, 33.2)	97.5 (95.8, 99.3)	15.4 (11.3, 19.5)	-6.4 (-0.3, 13.1), 0.06	12.1 (5.3, 19.0), <0.01
Composite ref	erence standard (C	RS)				
Xpert + CXR	90.6 (88.3, 92.9)	25.7 (22.2, 29.1)	89.3 (86.8, 91.7)	32.2 (28.5, 35.9)	1.0 (-1.9, 4.0), 0.58	-6.8 (-11.9, -1.7), <0.01
Xpert	88.9 (86.5, 91.4)	28.1 (24.5, 31.6)	94.2 (92.4, 96.1)	15.4 (12.5, 18.2)	-5.6 (2.1, 9.2), <0.01	12.1 (5.3, 19.0), <0.01
CXR	89.8 (87.4, 92.2)	25.7 (22.2, 29.1)	89.3 (86.8, 91.7)	32.2 (28.5, 35.9)	0 (-2.9, 3.4), 1.00	-6.8 (-11.9, -1.7), <0.01
None	87.5 (84.9, 90.2)	28.1 (24.5, 31.6)	94.2 (92.4, 96.1)	15.4 (12.5, 18.2)	-7.0 (-10.7, -3.2), <0.01	12.1 (5.3, 19.0), <0.01
Microbiologic reference standard (MRS)						
Xpert + CXR	97.6 (96.4, 98.8)	16.8 (13.9, 19.8)	96.3 (94.9, 97.8)	20.4 (17.2, 23.5)	1.2 (-2.3, 4.7), 1.00	-3.3 (-0.3, 6.2), 0.02
Xpert	97.6 (96.4, 98.8)	19.1 (16.0, 22.2)	97.5 (96.3, 98.8)	10.1 (7.7, 12.4)	0 (-1.2, 1.2), 1.00	9.1 (5.4, 12.9), <0.01
CXR	93.7 (91.8, 95.6)	16.8 (13.9, 19.8)	96.3 (94.9, 97.8)	20.4 (17.2, 23.5)	-2.5 (-3.7, 8.8), 0.62	-3.3 (-0.3, 6.2), 0.02
None	91.2 (89.0, 93.4)	19.1 (16.0, 22.2)	97.5 (96.3, 98.8)	10.1 (7.7, 12.4)	-6.4 (-0.3, 13.1), 0.06	9.1 (5.4, 12.9), <0.01

Xpert: Xpert MTB/RIF Ultra; CXR: Chest x-ray

1. Algorithm A used in scenarios with CXR, Algorithm B in scenarios without CXR